{
  "id": 5310814,
  "title": "Immune drug anifrolumab linked to lower risk of infection and hospitalization for skin lupus",
  "url": "https://urgent.news/2026/09/03/immune-drug-anifrolumab-linked-to-lower-risk-of-infection-and",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-03T11:00:02.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-immune-drug-anifrolumab-linked-infection.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Preliminary results from an investigator-initiated, single-site clinical study show that some people with chronic cutaneous lupus erythematosus—a type of lupus that can cause permanent skin damage and hair loss—are less likely to acquire life-threatening infections when taking the drug anifrolumab, an FDA-approved monoclonal antibody treatment for systemic lupus erythematosus.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}